NICE recommends use of Fasenra in eosinophilic asthma.- AstraZeneca.

The National Institute for Health and Care Excellence has recommended that Fasenra (benralizumab), from AstraZeneca, be available to people with severe eosinophilic asthma on the NHS in England and Wales. The therapy is given with a dosage as an injection every four weeks for the first three doses, and every eight weeks thereafter. This makes it potentially more convenient than Nucala (mepolizumab), which is also injected, but every four weeks.

In an earlier appraisal consultation document, NICE had concluded that the drug was not cost-effective, but an improved patient access scheme from AZ helped overturn this position.